Back

When should we prolong DAPT beyond 12 months?

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions Antiplatelet Agents ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mrinal Kanti Das

B M Birla Heart Research Centre, Kolkata (India)

3 More presentations in this session

Presentation thumbnail
De-escalation vs. early cessation of DAPT for patients at high bleeding risk
Doctor P. Rath (Hyderabad, IN)
Slides Video
Presentation thumbnail
Is aspirin the preferred monotherapy after DAPT?
Professor B. Rocca (Casamassima, IT)
Slides Video
Presentation thumbnail
Machine learning to determine the optimal mode and duration of DAPT
Doctor B. Vogel (San Diego, US)
Slides Video

Access the full session

Session thumbnail
Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months: pro
thumbnail
Congress Presentation
De-escalation vs. early cessation of DAPT for patients at high bleeding risk
thumbnail
Congress Session
Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources